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Introduction
Hemophilia A is a genetic disorder caused by deficiency of coagulation factor VIII (FVIII) resulting in reduced Factor X (FX) activation and consequently impaired clot formation. Severe hemophilia A is associated with spontaneous hemorrhage, particularly affecting joints. The current standard of care for severe hemophilia A is replacement therapy with plasma-derived or recombinant FVIII (rFVIII) [1, 2] . FVIII gene therapy is now under clinical evaluation [3, 4] .
Endogenous human FVIII consists of a heterodimer of a 90-200-kDa heavy chain with the A1-domain, A2-domain and B-domain and an 80-kDa light chain with the A3-domain, C1-domain and C2-domain connected by a metal ion bridge. The variable molecular weight of the heavy chain results from intracellular heterogeneous proteolytic processing of the 908 amino acid (aa) B-domain (aa 741-1648) [5] [6] [7] [8] . Similar heterogeneity is seen in rFVIII produced in mammalian cell cultures transfected with cDNA encoding wild-type FVIII [9] [10] [11] . In spite of the processing within the B-domain, both the latter rFVIII and plasma-derived FVIII are referred to as full-length FVIII.
Activation of FVIII involves removal of the B-domain, which is not involved in the hemostatic effect of activated FVIII. This has inspired the exploration and development of rFVIII compounds with no or a shortened B-domain of typically 10-30aa. These rFVIII proteins are produced in higher amounts from cell cultures than full-length rFVIII, and have the same pharmacokinetic and pharmacodynamic properties as full-length rFVIII and plasmaderived FVIII [5, 8, [12] [13] [14] [15] [16] .
Interestingly, Miao et al. [17] reported increased amounts of FVIII in supernatants from cells expressing rFVIII with intermediate-length B-domains as compared with rFVIII lacking the B-domain. The maximum FVIII content in supernatants was reached with a 226aa B-domain (aa 741-966). As compared with rFVIII with a B-domain of up to 14aa, FVIII with the 226aa B-domain also increased the in vivo levels of circulating FVIII in mice upon hydrodynamic injection of FVIII-coding DNA and in murine gene therapy models [17] [18] [19] [20] .
In the present study, we demonstrate that the length of the B-domain also plays a role in the pharmacokinetic profile of FVIII in F8-knockout (KO) mice. FVIII molecules with intermediate-length B-domains had extended half-lives in F8-KO mice as compared with full-length FVIII and FVIII with a 21aa B-domain . FVIII with an intermediate-length B-domain did not have reduced in vitro affinity for LDL receptor-related protein 1 (LRP-1), which is implicated in FVIII clearance; however, binding to LRP-1-expressing cells was reduced. This suggests an inhibitory role of the intermediate-length B-domain in an initial cell-binding step involved in FVIII cellular uptake.
Materials and methods

Proteins
For production of FVIII B-domain variants by transient expression, FVIII-coding DNA was inserted into the pTT5 expression vector [21] . All of these constructs contain a His-tag (in contrast to FVIII-21) and also Ser1637. Hybrid of kidney and B (HKB11) cells [22] were transiently transfected with the pTT5-based DNA constructs by use of the 293fectin transfection reagent (Life Technologies, Carlsbad, CA, USA), and cultivated in shaker flasks or cell culture bags. FVIII-21 was turoctocog alfa (NovoEight; Novo Nordisk A/S, Bagsvaerd, Denmark) produced from a stable Chinese hamster ovary (CHO) cell line with a vector encoding FVIII with a 21aa B-domain inserted [23] . For FVIII with a B-domain containing the 225 N-terminal aa fused to the 12 C-terminal aa of the wild-type B-domain (FVIII-237), a CHO production cell line encoding the 237aa/N6 protein was generated essentially as described previously [23] . FVIII from stably transfected CHO cell culture supernatants was purified with a three-step method consisting of two affinity chromatography steps, i.e. VIIISelect (GE Healthcare Life Sciences, Uppsala, Sweden) and F25 antibody [23] , followed by anion exchange chromatography on a Poros 50 HQ column (Thermo Fisher Scientific, Uppsala, Sweden). FVIII variants transiently expressed in HKB11 cells were purified with a three-step method consisting of two affinity chromatography steps, i.e. VIIISelect (GE Healthcare Life Sciences) and Chelating Sepharose FF (GE Healthcare Life Sciences), followed by anion exchange chromatography on a Poros 50 HQ column (Thermo Fisher Scientific).
A baby hamster kidney (BHK) cell line secreting a monomeric VWF fragment comprising the D 0 D3A1-domains (human von Willebrand factor [VWF] residues 764-1464 with Cys1099 and Cys1142 replaced with Ser) extended with a C-terminal human protein C (HPC4)-tag was generated essentially as described previously [24] , and transferred to a bioreactor for fed batch cultivation. An isolated intermediate-length B-domain fragment consisting of FVIII aa 741-966 and a C-terminal HPC4-tag was expressed in transiently transfected human embryonic kidney 293 (HEK293) cells. D 0 D3A1 and the B-domain fragment from cell culture supernatants were isolated with an affinity purification step on an anti-HPC4 column (SigmaAldrich, St. Louis, MO, USA). D 0 D3A1 was further purified by anion exchange chromatography on a Poros 15 HQ column (Thermo Fisher Scientific).
The 20aa B-domain peptide (aa 741-750 + 1638-1647) was synthesized on a Liberty Microwave Peptide Synthesizer (CEM Corporation, Matthews, NC, USA), with preloaded Fmoc-Gln(Trt)-Wang resin and standard Fmoc-protected amino acids from Novabiochem (Darmstadt, Germany) or Sigma-Aldrich.
LRP-1 cluster II was generated as described previously [25] .
FVIII specific activity
FVIII activity was determined in a chromogenic FVIII assay (Coatest SP; Chromogenix, M€ olndal, Sweden) as described previously [23] . An in-house FVIII-21 standard calibrated against the 7th International Standard Factor VIII Concentrate (NIBSC code 99/678) was used as calibrator. Specific activity was calculated by dividing the FVIII activity by the protein concentration. The protein concentration was determined by comparing the area under the curves of samples analyzed by reversed-phase HPLC with a known FVIII-21 sample, as described previously [23] .
In vivo studies
All animal studies were performed according to guidelines from and approved by the Danish Animal Experiments Council, the Danish Veterinary and Food Administration. The pharmacokinetics of FVIII B-domain variants were assessed after a single intravenous bolus administration to F8-KO and VWF-KO mice, with a previously described blood-sampling method [15] . For the FVIII variants shown in Fig. 1 (except for one), blood was sampled at three time points from each mouse (5 h, 24 h, and 30 h or 48 h; six mice per time point). For 129aa/N3, blood was sampled at nine time points in the interval of 5 min and 41 h, with two mice per time point. For the data shown in Fig. 2 , the blood-sampling time points were as shown on the graphs (two to four mice per time point). Blood samples were analyzed for activity as described above and in an ELISA (Asserachrom VIII:CAg; Diagnostica Stago, Asni eres-sur-Seine, France) with compound-specific calibrators. The half-lives of FVIII B-domain variants expressed by transient expression were estimated by linear regression of the log-concentration-time dataset, followed by descriptive statistics computing the mean half-life and 95% confidence intervals (CIs) with SAS JMP (v. 8.0, Cary, NC, USA). For further characterization of FVIII-21 and FVIII-237, concentration-time profiles were obtained as described previously [15] , and the pharmacokinetic parameters were estimated by means of a population approach using a one-compartment model (Pharsight PHOENIX 6.4 NLME 1.3; Princeton, NJ, USA). The hemostatic effect in vivo was analyzed in F8-KO mice fully anesthetized with isoflurane. FVIII-237 (0.5 IU kg À1 and 2 IU kg À1 ) or a dose range of FVIII-21 were administered intravenously, 5 min prior to transection of a tail vein. Bleeding time and blood loss were recorded with the tail immersed in saline at 37°C, as described previously [26] . ). Bound FVIII was detected with an in-house biotinylated anti-FVIII A2-domain antibody (1F5) [27] . Binding constants were derived by fitting the data with GRAPHPAD PRISM 7 (San Diego, CA, USA).
VWF, B-domain and LRP-1 binding determined with surface plasmon resonance (SPR)
Proteins were immobilized by standard amine coupling to a CM5 chip in a Biacore T200 instrument (GE Healthcare Life Sciences). Binding was assessed by passing the various analyte (D 0 D3A1, the B-domain fragment, or LRP-1 cluster II) concentration series over FVIII captured on immobilized anti-FVIII A2-domain antibody 10F93 (in-house) or anti-FVIII C2-domain antibody EL14 [28] . Data were double-referenced (corrected for background binding to an antibody-coupled reference cell and the averaged blank). Binding constants were derived by fitting the observed sensorgrams to 1 : 1 binding by the use of Biacore T200 EVAL-UATION software 3.0 (Uppsala, Sweden). Table S2 . (C) F8-KO mice anesthetized with isoflurane were intravenously injected with 0.15-5 IU kg À1 FVIII-21 or 0.5 IU kg À1 and 2.0 IU kg À1 FVIII-237 5 min prior to tail vein transection.
Bleeding was assessed with the tail immersed in saline at 37°C as total bleeding time (left) and blood loss (right) (mean AE standard error of the mean, n = 12). aa, amino acids; HA, hemophilia A.
Canada). Alternatively, cell binding or internalization of FVIII-21 glycoconjugated with Alexa Fluor-647 [29] was analyzed by flow cytometry after 30 min of incubation at 4°C and scraping off the cells, or after 30 min of incubation at 37°C followed by protease treatment, respectively.
Results
FVIII variants with different B-domain lengths produced by transient expression
A selection of FVIII proteins with intermediate length B-domains including different numbers of N-glycan sites were designed, transiently expressed in HEK293-derived HKB11 cells, and purified (Fig. 1A) . The FVIII variants were inspired by those described by Miao et al. [17] , but differed by including aa 1637-1648 from the C-terminal part of the B-domain containing the furin cleavage site. Therefore, the present FVIII variants were secreted predominantly as heterodimers (Fig. S1 ). Furthermore, a His-tag was incorporated into the B-domain and utilized for protein purification. In most cases, the His-tag was inserted near the C-terminus of the B-domain, in order to obtain a homogeneous B-domain of the expected length after purification (Fig. 1A) . However, purification of FVIII variants with B-domains longer than 237aa followed by a His-tag proved challenging. This was overcome by moving the His-tag to the N-terminus of the B-domain (Fig. 1B) . The purified proteins had specific activities of 1.0-1.3 9 10 4 IU mg À1 (Table S1 ).
Pharmacokinetics of FVIII B-domain variants
The pharmacokinetics of the FVIII variants were examined in F8-KO mice. In these mice, the half-life of FVIII-21 is ≈ 7 h [15] , whereas the half-life of FVIII with a 21aa B-domain produced by transient expression in HEK293-derived HKB11 cells was ≈ 5 h (data not shown). The same half-life (4.6 h [95% CI 4.0-5.3 h]) was found for the His-tagged FVIII protein 22aa/N0, also produced by transient expression (Fig. 1C) . Faster clearance of glycoproteins produced by HEK293 cells than of the same proteins produced by CHO cell lines have previously been reported, and this is often attributed to different glycoprofiles [30, 31] . The half-life of 129aa/N3 was comparable to that of 22aa/N0 (Fig. 1C) . However, the half-lives of 186aa/N4, 226aa/N5, 237aa/N6 and 240aa/N6 were significantly longer than the half-life of 22aa/N0, as the 95% CIs did not overlap. As 237aa/N6 and 240aa/N6 differed only by three amino acid residues and the position of the His-tag (Fig. 1A,B) , the similar half-lives of these two B-domain variants demonstrated that the position of the His-tag did not have a noticeable effect on the half-life. The half-life of 342aa/N10 was not significantly different from that of 22aa/N0 (Fig. 1C) , indicating that the extended half-life was a feature of FVIII molecules with B-domains of 186aa (and possibly shorter) up to between 240aa and 342aa.
To examine the role of B-domain N-glycans in half-life extension, a 237aa/N6 variant with Gln substitutions eliminating the six N-glycosylation sites was produced (237aa/N0). On the basis of overlapping 95% CIs, the half-life of the latter FVIII variant was not significantly different from that of 237aa/N6 (Fig. 1C) , suggesting no role of the N-glycans in the B-domain in the observed half-life extension.
The pharmacokinetics of the FVIII B-domain variants 22aa/N0 and 237aa/N6 were compared in VWF-KO mice. The half-life of 22aa/N0 was estimated to be 0.1 h, whereas the half-life of 237aa/N6 was 1.1 h, demonstrating an extended half-life also in the absence of VWF (Fig. 2A) .
The properties of 237aa/N6 were further analyzed by the use of protein produced by a stably transfected CHO cell line. This CHO cell-derived FVIII with a 237aa B-domain (FVIII-237) had a half-life of 11.7 AE 1.3 h in F8-KO mice, i.e. 1.6-fold longer than the 7.2 AE 1.1 h for FVIII-21 (Fig. 2B) . A B-domain of 237aa therefore led to an extended half-life, independently of the production method used.
In vitro and in vivo activity of FVIII-237
The specific activity of FVIII-237 was 9.0 AE 2.3 9 10 3 IU mg À1 (mean AE standard deviation of five batches), which is comparable to that of FVIII-21 (9.6 AE 0.4 9 10 3 IU mg À1 [27] ). The in vivo activity of FVIII-237 was evaluated in a tail vein transection model in F8-KO mice [26] . FVIII-237 was administered intravenously to F8-KO mice, and bleeding was assessed 5 min after injury. When compared with the effect of FVIII-21 (Fig. 2C) , the tested doses of FVIII-237 overlapped with the dose-response curve of FVIII-21, suggesting that FVIII-237 has comparable acute in vivo activity to FVIII-21.
VWF binding
VWF plays an essential role in the FVIII half-life, and the extended half-life of FVIII-237 could potentially be a result of increased affinity for VWF. VWF binding was therefore measured with ELISA and SPR analysis (Fig. 3) . In the ELISA, the K d for binding to immobilized VWF (Fig. 3A (Fig. 3C) or FVIII-237 (Fig. 3D) was measured with SPR. The resulting binding curves were similar for FVIII-21 and FVIII-237, and both fitted well to a 1 : 1 binding equation (Fig. 3C,D; Fig. S2 ). K d values of 62 AE 0.4 nmol L À1 and 71 AE 0.9 nmol L À1 were obtained for FVIII-21 and FVIII-237, respectively. These K d values are higher than determined with ELISA, which can be attributed to a combination of using D 0 D3A1 instead of full-length VWF, and by immobilization of VWF in microtiter wells versus capturing FVIII with an antibody. As FVIII-21 and FVIII-237 are always compared within the same setting, the data together demonstrated that FVIII-237 does not bind more strongly to VWF than FVIII-21. The extended half-life of FVIII-237 was therefore not attributable to an increased affinity for VWF. Direct binding of FVIII-21 and FVIII-237 to LRP-1 was then investigated with SPR (Fig. 5A,B) . LRP-1 contains four clusters of complement-type repeats, three of which have been shown to mediate FVIII binding, i.e. clusters II, III, and IV [35] [36] [37] . To simplify the assay setup to 1 : 1 binding, the isolated cluster II from LRP-1 was used, as this cluster has the strongest affinity for FVIII [32] . binding equation could not be used, owing to the presence of multiple binding sites for FVIII in LRP-1 ( Fig. S3F-H , respectively). As the FVIII variants were always compared within the same setting, the data are collectively in support of the affinity for LRP-1 not being reduced for FVIII-237 as compared with FVIII-21. We speculated whether the isolated N-terminal 226aa B-domain fragment could interact with other regions in the FVIII-21 molecule, thereby shielding it from binding to cells. In order to investigate this possibility, binding of the B-domain fragment to antibody-captured FVIII-21 was analyzed with SPR (Fig. 7) . Concentration-dependent binding of the B-domain fragment was observed. The binding curves were fitted to a 1 : 1 binding equation, resulting in a calculated K d of 400 nmol L À1 (Fig. 7) . The binding may well be stronger when the B-domain is bound to the remaining FVIII, owing to an avidity effect.
In addition, in a reverse setup, FVIII-21 was shown to bind to the B-domain fragment (Fig. S4) ; however, these data could not be fitted to a 1 : 1 binding equation, so no K d was determined. Together, the data imply a direct interaction between the N-terminal 226aa B-domain and other domains of the FVIII molecule. Further studies are required to confirm the binding and its affinity, and the role of the N-linked glycans.
Discussion
The first evidence for altered properties of FVIII with an intermediate-length B-domain was presented by Miao et al. [17] , who demonstrated increased FVIII levels in supernatants from COS-1 and CHO cells expressing FVIII with intermediate-length B-domains as compared with FVIII lacking the B-domain [17] . This finding was confirmed with HEK293 cells by Kolind et al. [38] , who additionally found that, under serum-free conditions, the increased FVIII levels in the supernatant were attributable to a significant decrease in FVIII binding to membranes of the FVIII-producing cells, rather than an increase in expression level. In the present study, we demonstrate reduced binding of FVIII with an intermediate-length B-domain (FVIII-237) to U87-MG cells (Fig. 4) , suggesting that FVIII with an intermediatelength B-domain has reduced cell binding across a wide range of cell types and cultivation conditions. In addition to modulating FVIII levels in cell cultures, constructs encoding FVIII with a 226aa B-domain have also resulted in higher circulating FVIII levels in murine gene therapy studies [17] [18] [19] . The latter finding may, in part, be connected to reduced cellular retention of FVIII upon expression. However, in the present study, we 
KCl, 11 mmol L À1 glucose, and 1 g L À1 bovine serum albumin.
Cells were lysed and scraped off, and the supernatant was analyszd for FVIII antigen with a polyclonal ELISA (Affinity Biologicals) with compound-specific calibrators. Data are mean AE standard error of the mean of five independent experiments. aa, amino acids.
demonstrated extended half-lives of FVIII molecules with intermediate-length B-domains as compared with FVIII molecules with shorter B-domains of 22aa and 129aa in F8-KO mice (Fig. 1C) . This suggests that reduced FVIII clearance may play a role in the higher circulating FVIII levels in murine gene therapy studies employing FVIII with intermediate-length B-domains. The present study suggests that the extended half-life is a feature of FVIII variants with B-domains of between 186aa (and possibly shorter) up to between 240aa and 342aa. The half-life extension was not dependent on Nlinked glycans, as FVIII with a 237aa B-domain, in which the six N-linked glycosylation sites were deleted, had a comparable half-life extension to FVIII-237 containing all N-glycans (Fig. 1C) . This is in contrast to the cell studies by Miao et al., in which removal of N-linked glycans within the B-domain did lower the FVIII levels in cell culture supernatants [17] . It is therefore likely that the mechanisms behind the extended half-life and the increased FVIII levels in cell culture supernatants induced by an Plasma-derived and rFVIII derived from the full-length sequence are processed in the B-domain, and therefore contain a heterogeneous mixture of FVIII molecules with different lengths of B-domains. These include FVIII molecules with B-domains of 78aa, 376aa, or 574aa, in addition to FVIII without any B-domain in the case of processing at the C-terminus of the A2 domain [10] . None of these are within the range in which we observed an extended half-life. This is in line with the similar half-lives of FVIII-21 and FVIII derived from the full-length sequence (Advate) in both mice [15] and humans [39] .
The half-life extension in F8-KO mice of FVIII-237 was similar to or slightly shorter than that of polyethylene glycol (PEG)-conjugated FVIII (1.6-fold for FVIII-237 [ Fig. 2B ] and 1.6-2.1-fold for PEG-conjugated FVIII variants [29, 40, 41] ). However, in VWF-KO mice, the half-life extension of FVIII-237 was more modest than that of PEG-conjugated FVIII. FVIII-237 had a half-life of 1.1 h in VWF-KO mice ( Fig. 2A) (versus 0.1 h for FVIII-21), which was significantly lower than the half-life of PEGconjugated FVIII molecules, i.e. between 5.7 h and 7.0 h [29, 40] . We speculated whether increased affinity of FVIII-237 for VWF could explain the more pronounced half-life extension of FVIII-237 in F8-KO mice (relative to PEGconjugated FVIII) than observed in VWF-KO mice. However, both ELISA and SPR data demonstrated comparable VWF binding for FVIII-237 and FVIII-21, ruling out the possibility that the extended half-life of FVIII-237 was caused by increased affinity for VWF (Fig. 3) .
FVIII is cleared predominantly by the liver, in which several receptors, including LRP-1, are capable of internalizing FVIII [42, 43] . With the use of an LRP-1-expressing cell line as a model cell line for FVIII uptake, decreased cell surface binding was observed for FVIII-237 as compared with FVIII-21. In addition, an isolated B-domain fragment, containing the same N-terminal 225aa as the B-domain in FVIII-237, was able to inhibit both cell binding and internalization of FVIII-21, whereas a 20aa B-domain fragment was unable to do so (Figs 4  and 6 ). These data suggest a role for the N-terminal 225aa of the B-domain in FVIII-237 in cell binding and uptake. When evaluated with SPR (Fig. 5) , the binding affinity of FVIII-237 for LRP-1 was, however, similar to that of FVIII-21, revealing no role for the B-domain's Nterminal 225aa in LRP-1 binding. Previous studies have, however, suggested that an initial cellular binding step for FVIII is required to preconcentrate FVIII on the cell surface before endocytosis via LRP-1 and other clearance receptors [34, 44] . This initial binding step might be reduced for FVIII-237. Further investigations are needed to fully understand this.
On the basis of the half-life extension of only FVIII B-domain variants with B-domains in the range of 186-240aa, we speculated whether FVIII contained stretches of acidic and basic residues within the B-domain that may modulate FVIII properties in a manner analogous to the acidic and basic regions in the B-domain of FV [45] . However, sequence analysis did not reveal any highly acidic or basic regions as observed in FV, at least not in the linear sequence. Nevertheless, SPR experiments suggested a weak interaction between the isolated intermediate-length B-domain fragment and other FVIII domains (Fig. 7) . In contrast to half-life extension by PEG conjugation, whereby the half-life increases with PEG size [29] , our pharmacokinetic data suggest half-life extension only for B-domains between 186aa and $ 300aa. The conformation of the intermediate-length B-domain might therefore be crucial in affecting areas on FVIII-21 that are important for the uptake of FVIII, whereas shorter, but also longer, B-domains may be unable to adopt the same conformation and are therefore unable to extend the half-life.
In summary, FVIII molecules with intermediate-length B-domains, such as FVIII-237, had extended half-lives as compared with FVIII molecules with shorter or longer B-domains. This extended half-life combined with efficient release from the FVIII-producing cells may provide clinically relevant FVIII levels in murine models of gene therapy [17] [18] [19] [20] . 
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